Goldman Sachs Maintains Sell on Ionis Pharmaceuticals, Raises Price Target to $37
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Salveen Richter maintains a Sell rating on Ionis Pharmaceuticals (NASDAQ:IONS) but raises the price target from $33 to $37.
August 02, 2024 | 4:37 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Goldman Sachs maintains a Sell rating on Ionis Pharmaceuticals but raises the price target from $33 to $37.
The Sell rating suggests a negative outlook, but the raised price target indicates some positive reassessment of the company's value. The mixed signals may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100